Assembly Bio Commences Early-Stage Study of Drug to Treat Hepatitis B Viral Infection
Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced Initiation of Phase 1b clinical study of its drug candidate ABI-H3733 for Chronic Hepatitis B Virus Infection